Charles River and BioTech Social Inc. Pursue Crowdfunding Partnership

About this update from Charles River Laboratories International, Inc.

Aim to Enhance Charles River Incubator and Accelerator Programs by adding crowdfunding features, aiding early-stage developers WILMINGTON, Mass., July 31, 2025--(BUSINESS WIRE)--Charles River Laboratories International, Inc. (NYSE: CRL) and BioTech Social Inc. (BSI) today announced the exploration of a potential client-centric collaboration to enable Charles River Incubator (CIP) and Accelerator (CAP) Program participants to access the BioTech Funding Portal, an investment crowdfunding platform for life science companies. "We’re thrilled to explore this collaboration that will open up an exciting new funding pathway to bridge innovation with the right audiences and investors. This dynamic approach would potentially streamline the delivery of medicine to patients," said Kerstin Dolph, Corporate Senior Vice President, Global Manufacturing, Charles River. "We’re always working to equip our clients with the tools and opportunities they need to fast-track drug development and therapies." If formalized, the contemplated strategic partnership would allow early-stage cell and gene therapy (CGT) developers to raise up to $5 million per year via the platform, accelerating development and enabling therapies to reach patients more quickly, because every moment matters. The BioTech Funding Portal, a subsidiary of BioTech Social Inc., exclusively lists life sciences companies, like participants of the CIP and CAP programs, acting as a conduit for crowdfunding of emerging biotech companies. "The mission of the BioTech Funding Portal is to harness the power of non-accredited investors to support research that might otherwise go unfunded – despite it addressing clear, unmet medical needs," said Neva West, PhD, CEO of BioTech Funding Portal. "Through our potential partnership with the CIP and CAP programs, we aim to help selected applicants cross the notorious funding ‘valley of death’ that so often threatens innovative, early-stage companies." Committed to Catalyzing CGTs from Discovery to CommercializationThe CIP and CAP programs were established in 2024, enabling developers to form a strong foundation for commercial viability. Benefits of both programs include consultative regulatory and quality expertise, and access to laboratory space and equipment. Building on the success of the inaugural CIP cohort, announced in April 2025, de...

View stock analysis, news, and events for Charles River Laboratories International, Inc.